Alpha Cognition Inc. - Common Stock (ACOG)
5.0800
-0.2600 (-4.87%)
NASDAQ · Last Trade: Mar 27th, 9:26 PM EDT
Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q4 Revenue Miss Amid Strong Alzheimer's Drug Launchchartmill.com
Via Chartmill · March 26, 2026

This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.
Via The Motley Fool · March 15, 2026

Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.
Via The Motley Fool · March 15, 2026

This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries.
Via The Motley Fool · March 5, 2026
Alpha Cognition's Q3 2025 results beat revenue estimates by 37% on strong sales of its Alzheimer's drug, ZUNVEYL, showing significant commercial momentum.
Via Chartmill · November 13, 2025
Via Benzinga · September 30, 2025
Via Benzinga · April 24, 2025
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
Via Benzinga · March 18, 2025
Via Benzinga · March 18, 2025

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits for blast-related brain injuries.
Via Benzinga · January 8, 2025

Invizyne Technologies opened on Nov. 13 at $11.10. Shares gained as much as 13% following the company's $15 million initial public offering. Additionally, Alpha Cognition opened on Nov. 12 at $7.00.
Via Talk Markets · November 17, 2024